DCS, a novel classifier system based on disulfidptosis reveals tumor microenvironment heterogeneity and guides frontline therapy for clear cell renal carcinoma [0.03%]
基于二硫键连接的新型分类系统DCS揭示透明细胞肾细胞癌肿瘤微环境异质性并指导一线治疗
Aimin Jiang,Wenqiang Liu,Ying Liu et al.
Aimin Jiang et al.
Background: Emerging evidence suggests that cell deaths are involved in tumorigenesis and progression, which may be treated as a novel direction of cancers. Recently, a novel type of programmed cell death, disulfidptosis,...
Association of overall survival benefit of radiotherapy with progression-free survival after chemotherapy for diffuse large B-cell lymphoma: A systematic review and meta-analysis [0.03%]
弥漫性大B细胞淋巴瘤化疗后无进展生存期与放疗总生存期获益相关性的系统评价和meta分析
Jingnan Wang,Xin Liu,Yunpeng Wu et al.
Jingnan Wang et al.
Objective: To evaluate whether improved progression-free survival (PFS) from radiotherapy (RT) translates into an overall survival (OS) benefit for diffuse large B-cell lymphoma (DLBCL). ...
Associations between blood glucose and early- and late-onset colorectal cancer: evidence from two prospective cohorts and Mendelian randomization analyses [0.03%]
基于两项前瞻性队列和孟德尔随机化分析探讨血糖与早发和晚发结直肠癌的关联
Chenyu Luo,Jiahui Luo,Yuhan Zhang et al.
Chenyu Luo et al.
Background: The incidence of early-onset colorectal cancer (EOCRC), which exhibits differential clinical, pathological, and molecular features compared to late-onset CRC (LOCRC), is rising globally. The potential differen...
Primary liver cancer organoids and their application to research and therapy [0.03%]
原发性肝癌类器官及其在研究和治疗中的应用
Xiaobin Zhu,Rajiv Trehan,Changqing Xie
Xiaobin Zhu
Primary liver cancer is a leading cause of death worldwide. To create advanced treatments for primary liver cancer, studies have utilized models such as 2D cell culture and in vivo animal models. Recent developments in cancer organoids have...
Precision radiation therapy in the modern era of multidisciplinary care in oncology: What matters to our patients and beyond? [0.03%]
精准放疗在肿瘤多学科综合治疗新时代的作用：如何让患者和更多的人了解其重要性？
Feng-Ming Spring Kong
Feng-Ming Spring Kong
Deep learning model based on primary tumor to predict lymph node status in clinical stage IA lung adenocarcinoma: a multicenter study [0.03%]
基于原发肿瘤的深度学习模型预测临床一期肺腺癌淋巴结状态：一项多中心研究
Li Zhang,Hailin Li,Shaohong Zhao et al.
Li Zhang et al.
Objective: To develop a deep learning model to predict lymph node (LN) status in clinical stage IA lung adenocarcinoma patients. Methods: ...
Shigui Zhu
Shigui Zhu
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking approach in cancer treatment, utilizing the immune system's capabilities to combat malignancies. This innovative therapy involves extracting T-cells from a patie...
Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors [0.03%]
建立转移性前列腺癌患者同源重组修复得分阈值以预测PARP抑制剂疗效
Diwei Zhao,Anqi Wang,Yuanwei Li et al.
Diwei Zhao et al.
Background: The homologous recombination deficiency (HRD) score serves as a promising biomarker to identify patients who are eligible for treatment with PARP inhibitors (PARPi). Previous studies have suggested a 3-biomark...
Burden of malignant mesothelioma in China during 1990-2019 and the projections through 2029 [0.03%]
1990年至2019年中国恶性间皮瘤疾病负担及2029年前的预测分布
Qiulin Huang,Youli Chen,Liyou Lian et al.
Qiulin Huang et al.
Objective: To provide the most up-to-date data on the burden of malignant mesothelioma (MM) and the projections through 2029 in China. Methods: ...
Advances on anticancer new drugs in China and the USA in 2020: from ongoing trial to drug approval [0.03%]
中国和美国2020年抗肿瘤新药研发进展：从临床试验到获批上市
Huiyao Huang,Huilei Miao,Jun Wang et al.
Huiyao Huang et al.
Objectives: To describe and compare the research and development (R&D) pipeline of cancer new drugs and newly approved drugs in China and the USA in 2020, thus to provide decision-making evidence for related stakeholders....